Squamous cell carcinomas of the tongue and oral cavity as secondary malignancies: what factors are implicated?

The pegylated liposomal doxorubicin (PLD) was introduced clinically in the 1990s and won FDA approvals for the treatment of Kaposi's sarcoma (1995) and ovarian cancer (2000). At present, it seems prudent to engage patients in a discussion of risks (of a secondary cancer) versus benefits.